Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch – CNBC

Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch  CNBC Recent Trends in GLP-1 Use and Spending in Medicare  KFF Eli Lilly’s Oral Obesity Drug Set for Medicare Coverage  Intellectia AI Medicare Coverage of Ozempic Could Change Weight Loss Treatment Options—CEO  Newsweek Medicare Will Start Paying for Weight Loss Drugs Soon […]

Eli Lilly Invests $3.5 Billion in America for Advanced Obesity Drugs Plant.

PULSE POINTS WHAT HAPPENED: Eli Lilly announced plans to invest over $3.5 billion to build a manufacturing plant in Pennsylvania’s Lehigh Valley to produce next-generation obesity drugs. WHO WAS INVOLVED: Eli Lilly, CEO Dave Ricks, President Donald J. Trump, and rival pharmaceutical company Novo Nordisk. WHEN & WHERE: The announcement was made on Friday, with […]

5 things to know about GLP-1 use in Medicare: KFF

Participating Medicare Part D plans can officially begin covering weight-loss treatment in 2027.  The initiative falls under CMS’ voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The December news followed President Donald Trump’s negotiations with Eli Lilly and Novo Nordisk to secure most-favored-nation pricing for drugs that treat […]

The Most Stunning Black Celebrity Weight Loss Transformations With GLP-1s!

As more and more of our favorite stars step out with newly slimmed-down physiques, one of the first questions many can’t help but ask is, “Did they, or didn’t they?” use GLP-1 medications that help lower blood sugar levels and reduce hunger to help them shed the pounds. But what was once a secret is […]

First GLP-1 Backed for MASH in Europe

Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis. Medscape News Europe

New GLP-1 Weight-Loss Drugs Expected This Year

This Medical News article discusses clinical trial data for weight-loss medications, in both injectable and pill formations, that are currently under review with US Food and Drug Administration.